CD133 is a membrane molecule that has been, controversially, reported as a CSC marker in colorectal cancer (CRC). In this study, we sought to clarify the expression and role of CD133 in CRC. Initially the size of the CD1332expressing (CD133+) population in eight well-described CRC cell lines was measured by flow cytometry and was found to range from 0% to >95%. The cell line HT29 has a CD133+ population of >95% and was chosen for functional evaluation of CD133 after gene knockdown by RNA interference. A time course assay showed that CD133 inhibition had no significant effect on cell proliferation or apoptosis. However, CD133 knockdown did result in greater susceptibility to staurosporine-induced apoptosis (p = 0.01) and reduction in cell mo...
Aims: The CD133 antigen has been identified as a putative stem cell marker in colorectal cancer t...
The cancer stem cell model suggests that only a rare subpopulation, known as cancer stem cells (CSC)...
[[abstract]]Background: Positive expression of CD44 and CD133 and high expression levels of an epith...
Objective. Stage I colorectal carcinomas display a highly variable behavior which is not accurately ...
INTRODUCTION: Recent evidence based on cancer stem cell (CSC) models, is boosting the progress of tr...
Summary: Background/Objective: CD133 is currently considered the most robust surface marker for col...
CD133 has recently been reported as a marker of cancer stem-like cells in colorectal cancer (CRC). H...
<div><h3>Objective</h3><p>CD133 has recently been reported as a marker of cancer stem-like cells in ...
Background: Colorectal cancer (CRC) is one of the most common malignancies in the world. The cancer ...
Objective: CD133 has recently been reported as a marker of cancer stem-like cells in colorectal canc...
Several surface markers have been proposed for the identification and characterization of colorectal...
CD133 is a pentaspan transmembrane glycoprotein of ~120 kDa, which was initially used to identify ha...
We previously reported that CD133, as a putative cancer stem cell marker, plays an important role in...
BACKGROUND: "Cancer stem cells" (CSC) have been identified as a minority of cancer cells responsibl...
Background: CD133 and CD44 are putative cancer stem cell (CSC) markers in colorectal cancer (CRC). H...
Aims: The CD133 antigen has been identified as a putative stem cell marker in colorectal cancer t...
The cancer stem cell model suggests that only a rare subpopulation, known as cancer stem cells (CSC)...
[[abstract]]Background: Positive expression of CD44 and CD133 and high expression levels of an epith...
Objective. Stage I colorectal carcinomas display a highly variable behavior which is not accurately ...
INTRODUCTION: Recent evidence based on cancer stem cell (CSC) models, is boosting the progress of tr...
Summary: Background/Objective: CD133 is currently considered the most robust surface marker for col...
CD133 has recently been reported as a marker of cancer stem-like cells in colorectal cancer (CRC). H...
<div><h3>Objective</h3><p>CD133 has recently been reported as a marker of cancer stem-like cells in ...
Background: Colorectal cancer (CRC) is one of the most common malignancies in the world. The cancer ...
Objective: CD133 has recently been reported as a marker of cancer stem-like cells in colorectal canc...
Several surface markers have been proposed for the identification and characterization of colorectal...
CD133 is a pentaspan transmembrane glycoprotein of ~120 kDa, which was initially used to identify ha...
We previously reported that CD133, as a putative cancer stem cell marker, plays an important role in...
BACKGROUND: "Cancer stem cells" (CSC) have been identified as a minority of cancer cells responsibl...
Background: CD133 and CD44 are putative cancer stem cell (CSC) markers in colorectal cancer (CRC). H...
Aims: The CD133 antigen has been identified as a putative stem cell marker in colorectal cancer t...
The cancer stem cell model suggests that only a rare subpopulation, known as cancer stem cells (CSC)...
[[abstract]]Background: Positive expression of CD44 and CD133 and high expression levels of an epith...